Study Confirms Dinutuximab Extends Life for Children with High-Risk Neuroblastoma - Cancer Currents Blog

The latest from the NCI Cancer Currents blog

Having trouble viewing this email? View it as a Web page.

You are subscribed to Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Recent posts are listed below.     Study Confirms Dinutuximab Extends Life for Children with High-Risk Neuroblastoma 09/06/2022 Researchers have confirmed that the immunotherapy drug dinutuximab (Unituxin) can help children with high-risk neuroblastoma live longer. The finding is based on a trial of nearly 1,200 children with the disease.

Stay Connected with the National Cancer Institute
Chat with us: LiveHelp       Call us: 1-800-4-CANCER (1-800-422-6237) SUBSCRIBER SERVICES: Manage Subscriptions  |  Help

 

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892